Personalised therapy is a clinical reality transforming patient care into a new paradigm of medicine fit for the technological realities of the 21st century. Central to these advances is our ever deepening understanding of how multifarious genetic variations and transcriptomic changes in coding and non-coding loci can be individually and jointly causal to disease. However, to date, there is no single DNA / RNA analytical method that can be truly undertaken in a laboratory infrastructure-free manner similar to blood glucose measurements. The Ebola virus disease outbreak in West Africa demonstrated clearly the need for bringing reliable RNA diagnostic tests to the patient: containment was achieved through mobile laboratory deployment of real time quantitative RT-PCR assays. The EbolaCheck consortium thus explored whether these assays can be performed directly on an unprocessed blood sample in an laboratory-free manner. This talk will cover the 12-month journey in developing QuRapID, an open access platform that quantifies known RNA and DNA targets in as little as five microliters of a fresh biofluid sample with comparable sensitivity and specificity to the lab based procedure. Applications in cancer diagnosis, septicaemia and gene therapy pharmacology will be discussed.
|Publication status||Published - Nov 2016|
|Event||2nd Congress of Pharmacogenomics and Personalised Diagnostics and Therapy - Athens|
Duration: 1 Nov 2016 → …
|Conference||2nd Congress of Pharmacogenomics and Personalised Diagnostics and Therapy|
|Period||1/11/16 → …|